Causes and consequences of lipoprotein(a) abnormalities in kidney disease (Q38152960)

29 August 2017

Causes and consequences of lipoprotein(a) abnormalities in kidney disease (English)

1 reference

29 August 2017

0 references

1 reference

Florian Kronenberg

1

1 reference

PubMed ID

24129557

29 August 2017

language of work or name

1 reference

16 October 2013

1 reference

Clinical and experimental nephrology

29 August 2017

1 reference

29 August 2017

18

1 reference

29 August 2017

234-237

1 reference

29 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s10157-013-0875-8

29 August 2017

0 references

cites work

Lipoprotein(a): resurrected by genetics

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Lipoprotein(a) and risk of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

The mysterious lipoprotein(a) is still good for a surprise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Lipoprotein metabolism and lipid management in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Urinary Excretion of Apo(a) Fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10157-013-0875-8

Inflammation enhances cardiovascular risk and mortality in hemodialysis patients

21 January 2018

1 reference

12 December 2020

Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up

1 reference

12 December 2020

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis

1 reference

12 December 2020

Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation

1 reference

12 December 2020

Apo(a) isoforms predict risk for coronary heart disease. A study in six populations

1 reference

12 December 2020

Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients

1 reference

12 December 2020

Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure

1 reference

12 December 2020

Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome

1 reference

12 December 2020

The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up.

1 reference

12 December 2020

Evidence for increased synthesis of lipoprotein(a) in the nephrotic syndrome.

1 reference

12 December 2020

In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients

1 reference

12 December 2020

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation

1 reference

12 December 2020

10.1007/S10157-013-0875-8

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

24129557